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patients with symptomatic venous
thromboembolism – the J-EINSTEIN DVT
and PE program’
Norikazu Yamada1*, Atsushi Hirayama2, Hideaki Maeda3, Satoru Sakagami4, Hiroo Shikata5, Martin H. Prins6,
Anthonie W. A. Lensing7, Masaharu Kato8, Junichi Onuma8, Yuki Miyamoto8, Kazuma Iekushi8 and Mariko Kajikawa8Unfortunately, the original version of this article [1] con-
tained errors. The errors have been addressed point by
point in full detail below.
Correction 1
Regarding primary efficacy endpoint (symptomatic re-
current VTE) and composite outcome of symptomatic
recurrent VTE or asymptomatic deterioration in rivarox-
aban group, we’ve found “1.3 %” (1 patient in 78 popula-
tion), is correct instead of current “1.4 %”, it should be
replaced in Page 1, Line 16 in the abstract section, and
on the right side of Page 5, Line 1. However, it is not ne-
cessary to replace the number “1.4%” in Table 3 because
it was calculated by another definition. Therefore we
also would like to add a description of the excluded
population, “patients assessed as “not evaluable” were
excluded from these analyses”, in footnotes of Table 2
and Table 3.
Correction 2
Due to changes made in correction 1, we need to re-
calculate absolute risk differences and 95 % Confidence
Interval of composite outcome of symptomatic recurrent
VTE or asymptomatic deterioration, and we consider
these numbers also need to be corrected. And to clarify
this “difference” means rivaroxaban reduces risk com-
pared to control, we would like to choose the absolute
risk “reduction” instead of “difference”. Absolute risk
“reduction” was 4.0 % compared to control, and 95 %
CI was (-2.9 to 24.0). We should change these num-
bers in Page 1, Line 17 in the abstract section, in the
right side of Page 5, Line 2 and in the right side of
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There was a trivial miscalculation of percentage in the
Table 3. Rivaroxaban combined result in DVT and PE
patients, 2 patients in 71 was evaluated as “unchanged”,
therefore percentage is “2.8 %” instead of current “2.9 %”.
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Abstract
Page 1
Line 15 to 17
The composite of symptomatic venous thromboembolic
events or asymptomatic deterioration occurred in 1 (1.4 %)
rivaroxaban patient and in 1 (5.3 %) UFH/warfarin patient
(absolute risk difference, 3.9 % [95 % confidence interval,
-3.4–23.8]).
The composite of symptomatic venous thromboembolic
events or asymptomatic deterioration occurred in 1 (1.3 %)
rivaroxaban patient and in 1 (5.3 %) UFH/warfarin patient





Line 23 to 25
Crude percentages and absolute differences and their
95 % confidence intervals were calculated.
Crude percentages and absolute reduction and their 95 %




Line 2 to 4
A single patient in the rivaroxaban group (1/78; 1.4 %)
developed symptomatic recurrent VTE compared with
none of the 19 patients allocated to control treatment.
A single patient in the rivaroxaban group (1/78; 1.3 %)
developed symptomatic recurrent VTE compared with




Line 9 to 12
VTE and asymptomatic deterioration at the end of
intended treatment occurred in 1 (1.4 %) rivaroxaban
patient and in 1 (5.3 %) control patient, with an
absolute risk difference of 3.9 % (95 % confidence
interval −3.4 to 23.8).
VTE and asymptomatic deterioration at the end of
intended treatment occurred in 1 (1.3 %) rivaroxaban
patient and in 1 (5.3 %) control patient, with an absolute
risk reduction of 4.0 % (95 % confidence interval




Line 5 to 8
At day 22, the combined venous ultrasound and lung
imaging result in patients with DVT and/or PE showed
normalization in 20 (26.7 %) of the 75 rivaroxaban
recipients and in 3 (15.8 %) of the 19 control patients.
At day 22, the combined venous ultrasound and lung
imaging result in evaluable patients with DVT and/or
PE showed normalization in 20 (26.7 %) of the 75






bid, twice daily, DVT, deep vein thrombosis; od, once
daily; PE, pulmonary embolism; UFH, unfractionated
heparin; VTE, venous thromboembolism.
*Symptomatic recurrent VTE during first 22 days.
bid, twice daily, DVT, deep vein thrombosis; od, once
daily; PE, pulmonary embolism; UFH, unfractionated
heparin; VTE, venous thromboembolism.
Patients assessed as "not evaluable" were excluded from











bid, twice daily, DVT, deep vein thrombosis; od, once
daily; PE, pulmonary embolism; UFH, unfractionated
heparin; VTE, venous thromboembolism.
*Symptomatic recurrent VTE during the entire
intended treatment period.
bid, twice daily, DVT, deep vein thrombosis; od, once
daily; PE, pulmonary embolism; UFH, unfractionated
heparin; VTE, venous thromboembolism.
Patients assessed as "not evaluable" were excluded from
these analyses. *Symptomatic recurrent VTE during the




Line 9 to 12
The lower limit of the confidence interval (i.e. –3.4 %)
around the absolute difference in the composite
efficacy outcome suggests that an important
deterioration in treatment effect can be excluded
for rivaroxaban.
The lower limit of the confidence interval (i.e. –2.9 %) around
the absolute reduction in the composite efficacy outcome
suggests that an important deterioration in treatment effect
can be excluded for rivaroxaban.
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